Full Question:
Which of the following describes the concept of an Enterprise Architecture Capability?

• A. The ability to strike a balance between positive and negative outcomes resulting from the realization of opportunities.
• B. The ability to develop, use and sustain the architecture of a particular enterprise using architecture to govern change.
• C. The ability to distinguish between different types of architectural assets that exist at different levels of abstraction in the enterprise.
• D. The ability to follow general rules and guidelines that relate to Enterprise Architecture work and that enable decision-making.

Please read this scenario prior to answering the question
You are serving as the Lead Architect for an Enterprise Architecture team within a leading multinational biotechnology company. The company works in three major industries, including healthcare, crop production, and agriculture. Your team works within the healthcare division.
The healthcare division is developing a new vaccine, and has to demonstrate its effectiveness and safety in a set of clinical trials that satisfy the regulatory requirements of the relevant health authorities. The clinical trials are undertaken by its research laboratories at multiple facilities worldwide. In addition to internal research and development activities, the healthcare division is also involved in publicly funded collaborative research projects with industrial and academic partners.
The Enterprise Architecture team has been engaged in an architecture project to develop a secure system that will allow the healthcare researchers to share information more easily about their clinical trials, and work more collaboratively across the organization and also with its partners. This system will also connect with external partners.
The Enterprise Architecture team uses the TOGAF ADM with extensions required to support healthcare manufacturing practices and laboratory practices. Due to the highly sensitive nature ofthe information that is managed, special care has been taken to ensure that each architecture domain considers the security and privacy issues that are relevant.
The Vice President for Worldwide Clinical Research is the sponsor of the Enterprise Architecture activity.
She has stated that disruptions must be minimized for the clinical trials, and that the rollout must be undertaken incrementally.
Refer to the scenario
You have been asked to recommend the approach to identify the work packages for an incremental rollout meeting the requirements.
Based on the TOGAF standard which of the following is the best answer?

• A. You recommend that the set of required Solution Building Blocks be determined by identifying those which need to be developed and which need to be procured. Eliminate any duplicates. Group the remaining Solution Building Blocks together to create the work packages using a CRUD (create, read, update, delete) matrix. Rank the work packages and select the most cost-effective options for inclusion in a series of Transition Architectures. Schedule the roll out of the work packages to be sequential across the geographic regions.
• B. You recommend that the Solution Building Blocks from a Consolidated Gaps, Solutions and Dependencies Matrix be grouped into a set of work packages. Using the matrix as a planning tool, regroup the work packages to account for dependencies. Sequence the work packages into the Capability Increments needed to achieve the Target Architecture, so that the implementation team can schedule the rollout one region at a time to minimize disruption. Document the work packages for the Enterprise Architecture using a Transition Architecture State Evolution Table.
• C. You recommend that a Consolidated Gaps. Solutions and Dependencies Matrix is used as a planning tool for creating work packages. For each gap classify whether the solution is either a new development, purchased solution, or based on an existing product. Group the similar solutions together to define the work packages. Regroup the work packages into a set of Capability Increments to transition to the Target Architecture considering the schedule for clinical trials, and document in an Architecture Definition Increments Table.
• D. You recommend that an Implementation Factor Catalog is drawn up to indicate actions and constraints.
  A Consolidated Gaps. Solutions and Dependencies Matrix should also be created. For each gap.
  identify a proposed solution and classify it as new development, purchased solution, or based on an existing product. Group similar activities together to form work packages. Identify dependencies between work packages factoring in the clinical trial schedules. Regroup the work packages into a set of Capability Increments scheduled into a series of Transition Architectures.

Which of the following best summarizes the purpose of Enterprise Architecture?

• A. Taking major improvement decisions.
• B. Controlling the bigger changes.
• C. Guiding effective change.
• D. Governing the Stakeholders.

Which of the following does the TOGAF standard describe as a package of functionality defined to meet business needs across an organization?

• A. A building block
• B. A deliverable
• C. A solution architecture
• D. An application